$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000161883519000147 Filed on August 06, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.634M	$6.695M	$11.41M
YoY Change	0.63%	-41.32%	798.43%
% of Gross Profit
Research & Development	$5.663M	$5.246M	$11.83M
YoY Change	-42.51%	-55.67%	190.17%
% of Gross Profit
Depreciation & Amortization	$70.00K	$60.00K	$60.00K
YoY Change	0.0%	0.0%	500.0%
% of Gross Profit
Operating Expenses	$14.30M	$11.94M	$23.24M
YoY Change	-22.44%	-48.62%	265.56%
Operating Profit	-$14.30M	-$11.94M	-$23.24M
YoY Change	-22.44%	-48.62%	265.56%
Interest Expense	$210.0K	-$23.50M	$30.00K
YoY Change	425.0%	-78433.33%	200.0%
% of Operating Profit
Other Income/Expense, Net	$499.0K	-$23.51M	$0.00
YoY Change	24850.0%		-100.0%
Pretax Income	-$13.80M	-$35.45M	-$23.24M
YoY Change	-25.14%	52.51%	256.91%
Income Tax	$0.00	$4.000K	$2.000K
% Of Pretax Income
Net Earnings	-$13.80M	-$35.45M	-$23.24M
YoY Change	-25.14%	52.51%	256.94%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$298.4K	-$965.2K	-$1.114M
COMMON SHARES
Basic Shares Outstanding	46.60M shares	35.37M shares	17.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$35.80M	$50.70M	$22.80M
YoY Change	195.87%	122.37%	200.0%
Cash & Equivalents	$32.12M	$50.68M	$22.79M
Short-Term Investments	$3.700M
Other Short-Term Assets	$1.500M	$1.900M	$1.300M
YoY Change	50.0%	46.15%	160.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$37.53M	$52.85M	$24.48M
YoY Change	179.59%	115.93%	202.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$546.0K	$461.0K	$717.0K
YoY Change	-16.26%	-35.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$596.0K	$622.0K	$977.0K
YoY Change	-37.26%	-36.34%	877.0%
Total Long-Term Assets	$1.457M	$1.566M	$1.694M
YoY Change	-9.05%	-7.56%	1594.0%
TOTAL ASSETS
Total Short-Term Assets	$37.53M	$52.85M	$24.48M
Total Long-Term Assets	$1.457M	$1.566M	$1.694M
Total Assets	$38.99M	$54.42M	$26.17M
YoY Change	159.48%	107.94%	219.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.163M	$8.567M	$7.998M
YoY Change	-35.74%	7.11%	1499.6%
Accrued Expenses	$6.453M	$7.217M	$11.10M
YoY Change	-55.33%	-35.01%	825.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.91M	$18.62M	$20.84M
YoY Change	-40.44%	-10.64%	1125.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.91M	$18.62M	$20.84M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$14.91M	$18.62M	$20.91M
YoY Change	-40.56%	-10.94%	1130.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$500.5M	-$486.7M	-$399.7M
YoY Change	19.68%	21.76%	203.54%
Common Stock	$524.5M	$522.5M	$405.0M
YoY Change	28.53%	29.0%	193.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$24.08M	$35.79M	$5.258M
YoY Change
Total Liabilities & Shareholders Equity	$38.99M	$54.42M	$26.17M
YoY Change	159.48%	107.94%	218.61%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$13.80M	-$35.45M	-$23.24M
YoY Change	-25.14%	52.51%	256.94%
Depreciation, Depletion And Amortization	$70.00K	$60.00K	$60.00K
YoY Change	0.0%	0.0%	500.0%
Cash From Operating Activities	-$14.42M	-$19.55M	-$19.19M
YoY Change	61.66%	1.88%	788.43%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$3.720M	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$3.740M	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-420.0K	70.03M	36.93M
YoY Change	-77.89%	89.63%
NET CHANGE
Cash From Operating Activities	-14.42M	-19.55M	-19.19M
Cash From Investing Activities	-3.740M	0.000	0.000
Cash From Financing Activities	-420.0K	70.03M	36.93M
Net Change In Cash	-18.58M	50.48M	17.74M
YoY Change	71.72%	184.55%	-921.3%
FREE CASH FLOW
Cash From Operating Activities	-$14.42M	-$19.55M	-$19.19M
Capital Expenditures	-$20.00K
Free Cash Flow	-$14.40M
YoY Change	61.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	46601058	shares
	evfm	Reclassification Of Warrants And Purchase Rights To Equity ReclassificationOfWarrantsAndPurchaseRightsToEquity	6120000	USD
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	9153000	USD
CY2019Q2	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	5299000	USD
CY2018Q4	evfm	Accrued Interest Unpaid Sublicense Fees AccruedInterestUnpaidSublicenseFees	174000	USD
CY2019Q2	evfm	Accrued Interest Unpaid Sublicense Fees AccruedInterestUnpaidSublicenseFees	174000	USD
CY2018Q4	evfm	Accrued Sublicense Fees AccruedSublicenseFees	1117000	USD
CY2019Q1	evfm	Accrued Sublicense Fees AccruedSublicenseFees	1300000	USD
CY2019Q2	evfm	Accrued Sublicense Fees AccruedSublicenseFees	1117000	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassification Of Purchase Rights Liability AdjustmentsToAdditionalPaidinCapitalReclassificationOfPurchaseRightsLiability	22800000	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassification Of Warrants AdjustmentsToAdditionalPaidinCapitalReclassificationOfWarrants	6900000	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassificationof Warrants And Purchase Rights Liability AdjustmentsToAdditionalPaidinCapitalReclassificationofWarrantsAndPurchaseRightsLiability	29726000	USD
CY2018Q2	evfm	Class Of Warrant Or Right Issued In Transaction ClassOfWarrantOrRightIssuedInTransaction	8500000	shares
CY2019Q2	evfm	Common Stock Reserved Upon Release Of Restricted Stock Units CommonStockReservedUponReleaseOfRestrictedStockUnits	151500	shares
CY2018Q1	evfm	Deemed Contribution Upon Exchange Of Preferred Stock DeemedContributionUponExchangeOfPreferredStock	49334000	USD
	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	800000	USD
	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	257000	USD
	evfm	Deferred Rent Adjustment DeferredRentAdjustment	207000	USD
	evfm	Deferred Rent Adjustment DeferredRentAdjustment	0	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment	300000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate	0.05
CY2019Q2	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	19600000	USD
CY2018Q2	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	0	USD
	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	0	USD
CY2019Q2	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	19617000	USD
	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	19617000	USD
	evfm	Gain Loss On Issuance Of Convertible Preferred Stock GainLossOnIssuanceOfConvertiblePreferredStock	-47920000	USD
	evfm	Gain Loss On Issuance Of Convertible Preferred Stock GainLossOnIssuanceOfConvertiblePreferredStock	0	USD
	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	0	USD
	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	378000	USD
CY2019Q2	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	700000	USD
CY2018Q2	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	0	USD
	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	0	USD
CY2019Q2	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	674000	USD
	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	674000	USD
CY2018Q2	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	47920000	USD
CY2019Q2	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
CY2018Q4	evfm	Notes Issued Stated Rate Monthly Percent Of Principal Permitted NotesIssuedStatedRateMonthlyPercentOfPrincipalPermitted	0.01
	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	37542000	USD
	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2019Q2	evfm	Purchase Right Liability PurchaseRightLiability	3200000	USD
	evfm	Reclassification Of Warrants And Purchase Rights To Equity ReclassificationOfWarrantsAndPurchaseRightsToEquity	0	USD
CY2019Q2	evfm	Warrant Liability WarrantLiability	3600000	USD
CY2018Q1	evfm	Warrants And Stock Issued During Period Value New Issues WarrantsAndStockIssuedDuringPeriodValueNewIssues	14062000	USD
CY2019Q1	evfm	Warrants And Stock Issued During Period Value New Issues WarrantsAndStockIssuedDuringPeriodValueNewIssues	10617000	USD
CY2019Q2	evfm	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	34200000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8882000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	8567000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11513000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7217000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	549000	USD
CY2019Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	376000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	604000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	736000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	409787000	USD
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	522451000	USD
CY2019Q1	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-6000	USD
CY2019Q2	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-518000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	80000000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	688000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10663000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1962000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2515000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10663000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11351000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2515000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4477000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8349526	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13041564	shares
CY2018Q4	us-gaap	Assets Assets	4010000	USD
CY2019Q2	us-gaap	Assets Assets	54415000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	2478000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	52849000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	904000	USD
CY2019Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	513000	USD
CY2019Q2	us-gaap	Cash Cash	50700000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1900000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22788000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1330000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50679000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23342000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51080000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1701000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23342000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1761000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	51080000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	21641000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	49319000	USD
CY2019Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.50
CY2019Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6369270	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13947893	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25867248	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46426315	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25867248	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46426315	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2017Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	80	shares
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	37000	USD
CY2019Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	131000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	132000	USD
CY2018Q2	us-gaap	Depreciation Nonproduction DepreciationNonproduction	65000	USD
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	100000	USD
CY2019Q2	us-gaap	Depreciation Nonproduction DepreciationNonproduction	66000	USD
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	100000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1300000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	1900000	USD
CY2017Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	5200000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.15
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.97
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.68
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2924000	USD
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2259000	USD
CY2019Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3300000	USD
CY2018Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2019Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3315000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7755000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11409000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20436000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6695000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12438000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23242000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92298000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35446000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53514000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1757000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-478000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1249000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4176000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-879000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-665000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	465000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	985000	USD
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	32000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	62000	USD
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	108000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	126000	USD
	us-gaap	Lease Cost LeaseCost	0	USD
	us-gaap	Lease Cost LeaseCost	319000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	609000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	201000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	408000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	29000	USD
CY2015Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P8M23D
CY2018Q4	us-gaap	Liabilities Liabilities	27366000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	18623000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4010000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54415000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27329000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	18623000	USD
CY2018Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-130000	USD
CY2019Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2018Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2019Q2	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	56816000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76295000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2150000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	250000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37325000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27226000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-69056000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-23244000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-92300000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-18068000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-35450000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-53518000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23244000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-433146000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-92366000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35450000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-53518000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	46000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-48070000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23505000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-27941000	USD
CY2018Q4	us-gaap	Notes Issued1 NotesIssued1	4000000	USD
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4010000	USD
CY2019Q2	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	23242000	USD
	us-gaap	Operating Expenses OperatingExpenses	44228000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	11941000	USD
	us-gaap	Operating Expenses OperatingExpenses	25573000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23242000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-44228000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11941000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25573000	USD
CY2018Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	96000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	254000	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	186000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	377000	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	600000	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	580000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	580000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	427000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	483000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	978000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	777000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	201000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	520000	USD
CY2019Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	251000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	939000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	622000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-32000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-82000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	200000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	157000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4477000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-486700000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-486664000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	802000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11351000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1197000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	593000	USD
CY2018Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	611000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	890000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	524000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	717000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1769000	USD
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	20000000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	75400000	USD
CY2016Q3	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	600000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	46000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6273000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1197000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	461000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4010000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11833000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23792000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5246000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13135000	USD
CY2018Q2	us-gaap	Restricted Cash RestrictedCash	554000	USD
CY2019Q2	us-gaap	Restricted Cash RestrictedCash	401000	USD
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	431000	USD
CY2019Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	401000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate	0.15
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	134375	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3270405	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	384000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	443000	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2018Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	121315000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	5226000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	46000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-289546000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-18292000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	5258000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-23356000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-28851000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	35792000	USD
CY2018Q1	us-gaap	Stockholders Equity Change In Reporting Entity StockholdersEquityChangeInReportingEntity	1946000	USD
CY2018Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	166.7000
CY2018Q1	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	223000	USD
CY2018Q2	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	66000	USD
CY2019Q2	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2018Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	14100000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20868554	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17937788	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36732568	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31941850	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:9pt;">S</font><font style="font-family:inherit;font-size:10pt;">ignificant estimates affecting amounts reported or disclosed in the consolidated financial statements include, but are not limited to: the discount rate used in estimating the fair value of the operating lease right-of-use (ROU) assets and operating lease liabilities, the measurement of the Series D 2X liquidation preference, assumptions used in estimating the fair value of warrants and Purchase Rights issued, the useful lives of property and equipment, the recoverability of long-lived assets, preclinical and clinical trial accruals, and assumptions used in estimating the fair value of stock-based compensation expense. The Company’s assumptions regarding the measurement of the Purchase Rights, the Series D 2X liquidation preference, and stock-based compensation are more fully described in </font><a style="font-family:inherit;font-size:10pt;" href="#sEF96DF23435E5624B6AE51888FCA8359"><font style="font-family:inherit;font-size:10pt;">Note 5 — Fair Value of Financial Instruments</font></a><font style="font-family:inherit;font-size:10pt;"> and </font><a style="font-family:inherit;font-size:10pt;" href="#s1445BDC4F44851228A7BB7E7AA6D91E6"><font style="font-family:inherit;font-size:10pt;">Note 12 — Stock-based Compensation, </font></a><font style="font-family:inherit;font-size:10pt;">respectively. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</font></div></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking and time deposit accounts are maintained in federally insured financial institutions in excess of federally insured limits. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances due to the financial position of the depository institutions in which these deposits are held.</font></div></div>

Files In Submission

Name	View Source	Status
0001618835-19-000147-index-headers.html	Edgar Link	pending
0001618835-19-000147-index.html	Edgar Link	pending
0001618835-19-000147.txt	Edgar Link	pending
0001618835-19-000147-xbrl.zip	Edgar Link	pending
evfm-20190630.xml	Edgar Link	completed
evfm-20190630.xsd	Edgar Link	pending
evfm-20190630_cal.xml	Edgar Link	unprocessable
evfm-20190630_def.xml	Edgar Link	unprocessable
evfm-20190630_lab.xml	Edgar Link	unprocessable
evfm-20190630_pre.xml	Edgar Link	unprocessable
evfm-630201910xq.htm	Edgar Link	pending
evfm-6302019ex311.htm	Edgar Link	pending
evfm-6302019ex312.htm	Edgar Link	pending
evfm-6302019ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2019 Q3 Form 10-Q Financial Statement

#000161883519000147 Filed on August 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2019 Q3 Form 10-Q Financial Statement

#000161883519000147 Filed on August 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm